Please assess the completion status of the following clinical trial:

Trial Title: Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~The most important criteria for patient eligibility include:~1. Age \>=18 years~2. Patients must have received prior therapy (any number of therapies) for WM and have relapsed or refractory WM~3. Eastern Cooperative Oncology Group performance score of 0 - 2~4. Hemoglobin \>= 10g/dL or hematocrit \>= 30%~5. Absolute neutrophil count (ANC) \>1000/mm3 and platelet count \>75,000/mm3~6. Adequate organ function defined as~   * serum glutamate pyruvate transaminase and serum glutamate oxaloacetate transaminase \< 2 x International Unit/l~  * Total bilirubin \>= 1.5 mg/dL~  * Clearance creatinin \> 50 ml/mn~7. Evaluable immunochemical abnormalities including abnormal electrophoresis and serum free light chain assay with an increase of either kappa or lambda light chain lev -~Exclusion Criteria:~Key Exclusion criteria~1. Any other uncontrolled medical condition or comorbidity that might interfere with subject's participation~2. Patients treated or requiring corticosteroids \>30mg/day~3. Pregnant or breast feeding females (Lactating females must agree not to breast feed while taking lenalidomide)~4. Use of any other experimental drug or therapy within 28 days of baseline~5. The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs~6. Known positive for HIV or infectious hepatitis, type A, B or C -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- revlimid (Type: OTHER): a dose-escalation of revlimid

Based on this trial design, predict the completion outcome and termination type (if applicable).